Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Liver & Bile Duct (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Percentlate
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank⋔
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late ascending
US (SEER+NPCR) 1 3.5 (3.5, 3.5) N/A 14,299 41.0
Georgia 3 4.7 (4.5, 4.9) 2 (2, 5) 584 56.2
Iowa 3 3.9 (3.6, 4.2) 12 (5, 23) 162 54.3
Louisiana 3 5.4 (5.1, 5.6) 1 (1, 2) 326 51.4
Connecticut 3 3.8 (3.5, 4.0) 15 (8, 24) 187 50.6
Kentucky 3 4.2 (4.0, 4.4) 8 (3, 13) 247 50.5
New York 3 4.3 (4.2, 4.5) 5 (3, 10) 1,103 50.0
Utah 3 3.1 (2.8, 3.4) 34 (21, 44) 92 49.4
Idaho 3 3.6 (3.3, 4.0) 21 (8, 34) 78 47.2
New Jersey 3 3.8 (3.6, 4.0) 13 (9, 22) 440 47.0
Rhode Island 6 4.3 (3.8, 4.8) 7 (2, 22) 60 46.5
Massachusetts 3 4.0 (3.8, 4.2) 10 (7, 18) 358 45.8
Hawaii 3 4.6 (4.1, 5.0) 3 (1, 12) 87 45.5
California 3 4.3 (4.2, 4.4) 6 (3, 10) 1,997 45.0
Missouri 6 3.6 (3.5, 3.8) 20 (10, 26) 299 44.8
South Dakota 6 3.0 (2.6, 3.5) 36 (15, 48) 34 44.2
Wisconsin 6 3.3 (3.1, 3.4) 26 (21, 37) 254 44.2
North Dakota 6 2.9 (2.4, 3.4) 38 (19, 49) 26 44.0
Mississippi 6 3.7 (3.5, 4.0) 16 (8, 26) 144 43.4
Vermont 6 2.6 (2.1, 3.1) 46 (24, 49) 24 43.4
Arkansas 6 3.7 (3.4, 4.0) 19 (9, 28) 145 43.1
Pennsylvania 6 3.7 (3.6, 3.8) 18 (11, 23) 663 43.0
North Carolina 6 3.7 (3.6, 3.8) 17 (10, 23) 501 42.6
Washington 5 3.8 (3.6, 4.0) 14 (9, 22) 360 42.5
Delaware 6 3.5 (3.1, 4.0) 22 (8, 40) 49 42.3
Nebraska 6 2.5 (2.2, 2.8) 47 (36, 49) 59 42.3
Alaska 6 4.0 (3.4, 4.7) 11 (2, 35) 32 42.0
Michigan 6 2.9 (2.8, 3.1) 37 (31, 43) 407 42.0
Montana 6 2.8 (2.4, 3.2) 41 (24, 49) 43 41.7
Florida 6 3.3 (3.2, 3.3) 27 (23, 34) 1,031 40.7
Maine 6 2.7 (2.4, 3.1) 43 (28, 49) 55 40.6
West Virginia 6 3.2 (2.9, 3.6) 28 (16, 41) 87 40.5
Illinois 3 3.2 (3.1, 3.4) 30 (23, 36) 519 40.0
Maryland 6 3.5 (3.3, 3.7) 23 (14, 31) 270 39.9
Minnesota 6 3.2 (3.0, 3.4) 32 (23, 40) 221 39.9
Ohio 6 3.0 (2.9, 3.2) 35 (29, 41) 477 39.7
Tennessee 6 3.4 (3.2, 3.6) 25 (18, 34) 300 39.4
Virginia 6 2.8 (2.7, 3.0) 40 (33, 46) 307 39.4
Kansas 6 2.9 (2.6, 3.1) 39 (28, 48) 105 39.3
South Carolina 6 3.1 (2.9, 3.3) 33 (23, 40) 220 39.1
Wyoming 6 2.1 (1.6, 2.6) 49 (39, 49) 17 38.6
Oregon 6 3.4 (3.2, 3.6) 24 (14, 35) 195 37.1
Texas 3 4.4 (4.3, 4.5) 4 (3, 9) 1,369 36.7
Colorado 6 2.7 (2.5, 2.8) 44 (37, 49) 179 36.6
New Hampshire 6 2.5 (2.2, 2.9) 48 (35, 49) 48 36.5
Oklahoma 6 3.2 (2.9, 3.4) 31 (22, 41) 157 35.7
Arizona 6 2.7 (2.6, 2.9) 42 (36, 47) 258 35.4
District of Columbia 6 4.0 (3.4, 4.7) 9 (2, 35) 29 34.7
New Mexico 3 3.2 (2.9, 3.6) 29 (17, 41) 92 33.0
Alabama 6 2.6 (2.4, 2.8) 45 (38, 49) 172 31.6
Puerto Rico 6 2.0 (1.8, 2.2) N/A 87 23.8
Indiana 6
data not available
N/A
data not available
data not available
Nevada 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 07/18/2024 4:06 pm.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
3 Source: SEER November 2022 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).
Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top